The acquisition is margin and EPS-accretive from the first year, although growth for the combined entity may fall to mid-single digits, compared to 10-12% for Sun Pharma alone, said Mehul Sheth, analyst at HDFC Securities. So, Sun Pharma may be overpaying at $14 a share, a 24% premium over already-rebounding levels.
